肢端肥大症治療市場規模、佔有率和成長分析（按疾病類型、診斷類型、治療類型和地區）- 產業預測 2025-2032

2023 年全球肢端肥大症治療市場規模價值14 億美元，預計將從2024 年的14.9 億美元成長到2032 年的23.9 億美元，預計在預測期內（2025-2032 年）到2032 年將達到14.9億美元)。

由於肢端肥大症盛行率不斷上升以及對創新治療方法的需求不斷增加，因此肢端肥大症治療市場預計將出現強勁成長。研發投入的快速成長推動製藥公司專注於創造新的藥物配方和給藥方法。遺傳疾病的流行和生活方式的改變預計會推動這種需求，特別是隨著荷爾蒙失調變得越來越普遍。特別是，強大的藥品管道，包括預期 FDA核准的新型生長激素受體拮抗劑和生長抑制素類似物，可能會進一步提升市場的潛力。放射線手術等檢測方法的技術進步將提高治療效果並減少副作用。此外，政府針對罕見疾病的支持政策和計劃可能會在未來幾年促進市場的擴張。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

肢端肥大症治療市場規模（依疾病類型）

• 市場概況
• 異位肢端肥大症
• 假性肢端肥大症

肢端肥大症治療市場規模（依診斷類型）

• 市場概況
• 醫學影像
• 實驗室測試

肢端肥大症治療市場規模（依治療類型分類）

• 市場概況
• 外科手術
• 藥物治療
• 放射治療

肢端肥大症治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Novartis AG（Switzerland）
• Ipsen Pharma（France）
• Pfizer Inc.（USA）
• Crinetics Pharmaceuticals, Inc.（USA）
• Strongbridge Biopharma plc（Ireland）
• Ionis Pharmaceuticals, Inc.（USA）
• Merck & Co., Inc.（USA）
• AbbVie Inc.（USA）
• Eli Lilly and Company（USA）
• AstraZeneca PLC（UK）
• Sanofi SA（France）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Hikma Pharmaceuticals PLC（UK）
• Lupin Ltd.（India）
• Recordati SpA（Italy）
• Xeris Biopharma Holdings, Inc.（USA）
• Peptron Inc.（South Korea）

結論和建議

Global Acromegaly Treatment Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.49 billion in 2024 to USD 2.39 billion by 2032, growing at a CAGR of 6.1% during the forecast period (2025-2032).

The acromegaly treatment market is poised for robust growth, driven by the rising incidence of the disease and the increasing demand for innovative therapies. With a surge in research and development investments, pharmaceutical companies are focused on creating new drug formulations and administration methods. The prevalence of hereditary conditions and lifestyle changes is expected to fuel this demand, especially as hormonal disorders become more common. Notably, a strong pharmacological pipeline, including anticipated FDA approvals for new growth hormone receptor antagonists and somatostatin analogues, will further elevate market potential. Technological advancements in detection methods like radiosurgery are set to enhance treatment efficacy and reduce side effects. Additionally, supportive government policies and programs for rare diseases will contribute to market expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acromegaly Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acromegaly Treatment Market Segmental Analysis

Global Acromegaly Treatment Market is segmented by Disease Type, Diagnosis Type, Treatment Type and region. Based on Disease Type, the market is segmented into Ectopic Acromegaly and Pseudo Acromegaly. Based on Diagnosis Type, the market is segmented into Medical Imaging and Medical Laboratory Test. Based on Treatment Type, the market is segmented into Surgery, Drug Therapy and Radiation Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acromegaly Treatment Market

The acromegaly treatment market is predominantly driven by the rising incidence of acromegaly, a rare endocrine disorder characterized by an overproduction of growth hormone. As awareness surrounding the condition increases and diagnostic capabilities enhance, more individuals are being identified and treated for acromegaly. This growing recognition of the disease correlates with heightened demand for effective therapeutic solutions, stimulating advancements in treatment options. Consequently, the escalating prevalence of acromegaly significantly propels the market forward, creating opportunities for pharmaceutical companies to innovate and expand their offerings in this specialized healthcare sector as patient needs evolve.

Restraints in the Global Acromegaly Treatment Market

The Global Acromegaly Treatment market faces significant restraints, primarily due to limited awareness and underdiagnosis of the condition. Although acromegaly is becoming more prevalent, many cases remain undetected or are diagnosed later than ideal because the symptoms develop gradually and are often non-specific. This lack of awareness among healthcare professionals and the general public contributes to delays in diagnosis and treatment, ultimately hindering the growth of the market. Addressing these awareness gaps is crucial for facilitating early detection and improving patient outcomes in acromegaly treatment.

Market Trends of the Global Acromegaly Treatment Market

The Global Acromegaly Treatment market is increasingly trending towards targeted therapies, significantly reshaping treatment approaches. This shift is characterized by the rising adoption of somatostatin analogs and growth hormone receptor antagonists, which adeptly address the underlying hormonal imbalances that contribute to acromegaly. By providing enhanced efficacy and improved tolerability compared to traditional treatments, these innovative therapies cater to the growing demand for personalized medicine. As awareness and diagnosis rates of acromegaly rise, coupled with advancements in pharmaceutical research, the market is projected to expand, driven by the continued development and commercialization of these specialized treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Acromegaly Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Ectopic Acromegaly
• Pseudo Acromegaly

Global Acromegaly Treatment Market Size by Diagnosis Type & CAGR (2025-2032)

• Market Overview
• Medical Imaging
• Medical Laboratory Test

Global Acromegaly Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Surgery
• Drug Therapy
• Radiation Therapy

Global Acromegaly Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Diagnosis Type, Treatment Type)
  • US
  • Canada
• Europe (Disease Type, Diagnosis Type, Treatment Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Diagnosis Type, Treatment Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Diagnosis Type, Treatment Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Diagnosis Type, Treatment Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crinetics Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xeris Biopharma Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Peptron Inc. (South Korea
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations